Stock Watch: Roche’s Long Shot Over Its Patent Cliff
Is Big Pharma Losing Its Defensive Investment Attributes?
The pharmaceutical sector has historically provided generalist fund managers with a defensive tilt to offset their more cyclical exposures. But the opening announcements of third-quarter earnings season may show this counterbalance is under threat.
